SYNTHESIS & CHARACTERIZATION OF NEW MACROMOLECULAR CONTRAST AGENTS

合成

• 批准号: 8169728
• 负责人: Robert Charles Brasch
• 金额: $ 0.71万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-12 至 2011-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8169728
• 关键词: Blood; Categories; Characteristics; Chemicals; Computer Retrieval of Information on Scientific Projects Database; Contrast Media; Data; Diagnostic; Effectiveness; Electrons; Funding; Grant; Image; Institution; MALDI-TOF Mass Spectrometry; Mass Spectrum Analysis; Measurement; Medical Imaging; Microvascular Permeability; Molecular; Molecular Weight; Organ; Pharmacologic Substance; Property; Research; Research Personnel; Resources; Role; Source; Structure; Tissues; United States National Institutes of Health; cancer imaging; flexibility; ionization; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Imaging contrast agents (or contrast media) are a category of diagnostic pharmaceuticals for enhancing the image contrast of organs/tissues and for displaying the organ function in medical imaging. Macromolecular contrast agents have found their important role in the characterization of microvascular permeability/leakiness of tumor vessels, due to their blood-pool characteristics. New polyethyleneglycol (PEG)-core dendrimeric contrast agents with well-defined structure, high degree of size homogeneity, synthetic flexibility, and high effectiveness in imaging, have been synthesized. Their average molecular weights (MW) and MW distribution will be obtained from mass spectrometry, which info will be highly valuable for the study of their structure-property relationship and for the guidance of our synthetic optimization. In addition, those new small molecular intermediates, which are attributed to the image contrast, need the structure characterization by mass spectrometry. For different macromolecular derivatives (MW 3,000 - 90,000), matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry is used for the measurements of their MW and MW distributions. For small molecular compounds (MW 100 - 2000), electron spray ionization (ESI) mass spectrometry is applicable. Mass spectra data will be correlated with the data from physical and imaging measurements, the relationship among chemical, physical and imaging properties will be sought for this new class of dendrimeric contrast agents. The mass spectra data are highly important and valuable in the synthesis of our new PEG-core dendrimeric contrast agents for cancer imaging.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 成像造影剂（或造影剂）是一类用于增强器官/组织的图像对比度并在医学成像中显示器官功能的诊断药物。由于其血池特性，大分子造影剂在表征肿瘤血管的微血管通透性/渗漏性方面发挥着重要作用。新型聚乙二醇（PEG）核心树枝状造影剂具有结构明确、尺寸均一性高、合成灵活性强、成像效率高的特点。它们的平均分子量（MW）和MW分布将通过质谱获得，这些信息对于研究它们的结构-性能关系和指导我们的合成优化非常有价值。此外，那些新的小分子中间体由于图像对比度较高，需要通过质谱进行结构表征。对于不同的大分子衍生物（MW 3,000 - 90,000），采用基质辅助激光解吸电离飞行时间（MALDI-TOF）质谱法测量其MW和MW分布。对于小分子化合物（MW 100 - 2000），电子喷雾电离（ESI）质谱法适用。质谱数据将与物理和成像测量的数据相关联，将为这种新型树枝状造影剂寻找化学、物理和成像特性之间的关系。质谱数据对于合成用于癌症成像的新型 PEG 核心树枝状造影剂非常重要且有价值。